Back

Select your region

Corporate

Europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Arrange a consultation about stem cells

Learn more

Get in touch with us today!

Would you like to find out more about our services? Fill out the form below and we will contact you as soon as possible to provide you with all the necessary information and answer your questions.

    We would like to point out that the personal data provided in the form will be processed by FamiCord Suisse, based in Switzerland (BusinessPark Zug Sumpfstrasse 26, 6302 Zug), for the purpose of contacting you by telephone in connection with the provision of service information.

    Image

    List of life saving
    transplantations

    List of uses for stem cells approved by the FamiCord Group’s laboratories:

    Image
    List of uses for stem cells approved by the FamiCord Group’s laboratories:
    Nr. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
    1701 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 48
    1702 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 52
    1703 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 58
    1704 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 61
    1705 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Poland 67
    1706 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 71
    1707 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 72
    1708 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 63
    1709 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 32
    1710 Apheresis Autologous Acute Myeloid Leukemia – Relapse Hematology 2024 Standard Therapy Germany 68
    1711 Apheresis Allogeneic Acute Myeloid Leukemia Relapse Hematology 2024 Standard Therapy Germany 33
    1712 Apheresis Allogeneic Amegakaryocytic/Congenital Thrombocytopenia Hematology 2024 Standard Therapy Poland 63
    1713 Apheresis Allogeneic Anaplastic Large Cell Lymphoma Hematology 2024 Standard Therapy Poland 52
    1714 Apheresis Allogeneic Angioimmunoblastic T-Cell Lymphoma Hematology 2024 Standard Therapy Poland 47
    1715 Apheresis Allogeneic B-Cell Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 19
    1716 Apheresis Allogeneic B-Cell Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 62
    1717 Apheresis Allogeneic B-Cell Progenitor Acute Lymphoblastic Leukemia High Risk Hematology 2024 Standard Therapy Poland 4
    1718 Apheresis Allogeneic Calr Positive Myelofibrosis Hematology 2024 Standard Therapy Poland 61
    1719 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2024 Standard Therapy Poland 60
    1720 Apheresis Allogeneic Chronic Myelogenous Leukaemia Hematology 2024 Standard Therapy Poland 62
    1721 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 10
    1722 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 35
    1723 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 42
    1724 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 49
    1725 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 72
    1726 Apheresis Allogeneic Chronic Neutrophilic Leukemia Hematology 2024 Standard Therapy Poland 71
    1727 Apheresis Allogeneic Fanconi Aplastic Anemia Hematology 2024 Standard Therapy Poland 20
    1728 Apheresis Allogeneic Follicular Lymphoma Hematology 2024 Standard Therapy Poland 48
    1729 Apheresis Allogeneic High Risk Acute Myeloid Leukaemia Hematology 2024 Standard Therapy Poland 15
    1730 Apheresis Allogeneic High Risk Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 69
    1731 Apheresis Allogeneic High-Risk Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 71
    1732 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 27
    1733 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 27
    1734 Apheresis Allogeneic Hodgkin Disease Hematology 2024 Standard Therapy Poland 28
    1735 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 23
    1736 Apheresis Allogeneic Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 71
    1737 Apheresis Allogeneic Infant Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 41
    1738 Apheresis Allogeneic Kutanes T-Zell-Lymphom, Mycosis Fungoides Hematology 2024 Standard Therapy Poland 72
    1739 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 51
    1740 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 64
    1741 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 66
    1742 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 52
    1743 Apheresis Autologous Morbus Hodgkin Hematology 2024 Standard Therapy Germany 63
    1744 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Poland 43
    1745 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 52
    1746 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 54
    1747 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 60
    1748 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1749 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1750 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1751 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1752 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1753 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
    1754 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 64
    1755 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
    1756 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
    1757 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1758 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1759 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 67
    1760 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 68
    1761 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 69
    1762 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
    1763 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 71
    1764 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 72
    1765 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
    1766 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1767 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
    1768 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1769 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
    1770 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
    1771 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
    1772 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 74
    1773 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
    1774 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
    1775 Apheresis Allogeneic Myelodysplastic Hematology 2024 Standard Therapy Poland 68
    1776 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 20
    1777 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 22
    1778 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 54
    1779 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 58
    1780 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
    1781 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 62
    1782 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
    1783 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1784 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1785 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1786 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
    1787 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
    1788 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 70
    1789 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 71
    1790 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 73
    1791 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 60
    1792 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 53
    1793 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 69
    1794 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 59
    1795 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
    1796 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 49
    1797 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 52
    1798 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 63
    1799 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 66
    1800 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 58